Time In Range
Hybrid closed-loop system provides glycemic benefits, may be cost-effective in pregnancy
An advanced hybrid closed-loop insulin delivery system is safe to use for pregnant women with type 1 diabetes and may provide some glycemic benefits, especially during overnight hours, according to a presenter.
Automated insulin delivery lowers HbA1c, improves time in range in type 2 diabetes
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.
Sotagliflozin improves time in range in basal insulin-treated type 2 diabetes
In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting.
Missing insulin doses linked to lower time in range for adults with diabetes
Adults with diabetes who use a smart pen for both basal and bolus insulin delivery have a reduction in time in range with each injection they miss over a 14-day period, according to data published in Diabetes Care.
Hybrid closed-loop system boosts time in range for pregnant women with type 1 diabetes
Pregnant women with type 1 diabetes achieved a higher time in range and had fewer complications with use of a hybrid closed-loop insulin delivery system compared with continuous glucose monitoring alone, according to a speaker.
More time in range lowers adverse pregnancy outcome risks for patients with diabetes
Among pregnant women with type 1 diabetes, more time in optimal glucose range at 12 weeks gestation was associated with lower risks for preeclampsia and large for gestational age infants, researchers reported.
Time in range, other CGM metrics linked to diabetic retinopathy risk in type 1 diabetes
Providers can use continuous glucose monitoring metrics as well as HbA1c to assess diabetic retinopathy risk for adults with type 1 diabetes, according to findings published in Diabetes Technology & Therapeutics.
Glycemia Risk Index bests time in range in assessing hypoglycemia for adults with diabetes
The new continuous glucose monitoring metric Glycemia Risk Index better assesses hypoglycemia risk than time in range, according to study data.
Tubeless hybrid closed-loop system boosts time in range for youths with type 1 diabetes
Children and adolescents with type 1 diabetes had an increase in time in range and reduction in HbA1c after starting a tubeless hybrid closed-loop insulin delivery system, according to study data
Hybrid closed-loop therapy increases time in range for pregnant women with type 1 diabetes
Hybrid closed-loop insulin delivery can increase time in range for pregnant women with type 1 diabetes with no safety concerns, according to trial findings presented at the European Association for the Study of Diabetes annual meeting.